Recent News

• 04.01.2025 - MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
• 03.25.2025 - MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
• 03.20.2025 - MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
• 03.19.2025 - MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

Recent Filings

• 04.01.2025 - 8-K Current report
• 04.01.2025 - EX-99.1 EX-99.1
• 03.28.2025 - PRE 14A Other preliminary proxy statements
• 03.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.28.2025 - EX-99.1 EX-99.1
• 03.28.2025 - 8-K Current report
• 03.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.26.2025 - 8-K Current report
• 03.21.2025 - 8-K Current report
• 03.21.2025 - EX-99.1 EX-99.1